JP7228900B2 - 操作されたナチュラルキラー細胞およびその使用 - Google Patents

操作されたナチュラルキラー細胞およびその使用 Download PDF

Info

Publication number
JP7228900B2
JP7228900B2 JP2019551736A JP2019551736A JP7228900B2 JP 7228900 B2 JP7228900 B2 JP 7228900B2 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 7228900 B2 JP7228900 B2 JP 7228900B2
Authority
JP
Japan
Prior art keywords
cells
suitably
engineered
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503891A5 (enExample
JP2020503891A (ja
Inventor
エイモン ピーター オドワイアー，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onk Therapeutics Ltd
Original Assignee
Onk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60937693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7228900(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onk Therapeutics Ltd filed Critical Onk Therapeutics Ltd
Publication of JP2020503891A publication Critical patent/JP2020503891A/ja
Publication of JP2020503891A5 publication Critical patent/JP2020503891A5/ja
Priority to JP2023017202A priority Critical patent/JP2023052980A/ja
Application granted granted Critical
Publication of JP7228900B2 publication Critical patent/JP7228900B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001126—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019551736A 2016-12-09 2017-12-11 操作されたナチュラルキラー細胞およびその使用 Active JP7228900B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023017202A JP2023052980A (ja) 2016-12-09 2023-02-07 操作されたナチュラルキラー細胞およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662432302P 2016-12-09 2016-12-09
US62/432,302 2016-12-09
PCT/EP2017/082292 WO2018104562A1 (en) 2016-12-09 2017-12-11 Engineered natural killer cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017202A Division JP2023052980A (ja) 2016-12-09 2023-02-07 操作されたナチュラルキラー細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2020503891A JP2020503891A (ja) 2020-02-06
JP2020503891A5 JP2020503891A5 (enExample) 2021-01-21
JP7228900B2 true JP7228900B2 (ja) 2023-02-27

Family

ID=60937693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019551736A Active JP7228900B2 (ja) 2016-12-09 2017-12-11 操作されたナチュラルキラー細胞およびその使用
JP2023017202A Pending JP2023052980A (ja) 2016-12-09 2023-02-07 操作されたナチュラルキラー細胞およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023017202A Pending JP2023052980A (ja) 2016-12-09 2023-02-07 操作されたナチュラルキラー細胞およびその使用

Country Status (12)

Country Link
US (2) US10799536B2 (enExample)
EP (4) EP3895712B1 (enExample)
JP (2) JP7228900B2 (enExample)
KR (1) KR20190114966A (enExample)
CN (2) CN110248669B (enExample)
AU (1) AU2017371517B2 (enExample)
BR (1) BR112019011450A2 (enExample)
CA (1) CA3045386A1 (enExample)
DK (2) DK3581190T3 (enExample)
ES (3) ES2746856T3 (enExample)
MX (1) MX2019006598A (enExample)
WO (1) WO2018104562A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB2567093A (en) * 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
DK3581190T3 (da) * 2016-12-09 2021-06-07 Onk Therapeutics Ltd Manipulerede naturlige dræberceller og anvendelser deraf
US20210228630A1 (en) * 2018-05-16 2021-07-29 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
JP7241161B2 (ja) * 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
TWI785268B (zh) * 2018-08-29 2022-12-01 中央研究院 用於治療癌症的自然殺手細胞與環磷醯胺的組合
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
EP3958875A4 (en) * 2019-04-25 2023-05-10 Purdue Research Foundation MANIPULATED NATURAL KILLER CELLS TARGETING PURINGERIC SIGNALING, THEIR CONSTRUCTS AND METHODS OF USE
AU2020375053A1 (en) * 2019-10-31 2022-05-26 Research Institute At Nationwide Children's Hospital Generation of CD38 knock-out primary and expanded human NK cells
US20230036481A1 (en) * 2020-01-16 2023-02-02 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells
KR20220027785A (ko) * 2020-08-27 2022-03-08 주식회사 셀리드 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신
US20240141295A1 (en) 2020-08-31 2024-05-02 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
CN114426583B (zh) * 2020-10-29 2023-10-10 中国科学技术大学 用于急性髓系白血病的细胞疗法的嵌合抗原受体
KR20220091426A (ko) 2020-12-23 2022-06-30 주식회사 휴먼셀바이오 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
JP2024522756A (ja) 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
WO2023278811A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
US20240327521A1 (en) * 2021-07-29 2024-10-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Synthetic nucleic acid elements for enhancing car t cell efficacy
CA3231204A1 (en) * 2021-09-18 2023-03-23 Feng Wang-Johanning Herv-k antibody, cell, vaccine, and drug therapeutics
KR20250005564A (ko) * 2021-12-03 2025-01-09 유타대학연구재단 고선택성 cd229 항원 결합 도메인 및 사용 방법
KR20250060188A (ko) 2022-06-30 2025-05-07 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 항체 요법의 조합 및 관련 방법
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024100203A1 (en) 2022-11-10 2024-05-16 Onk Therapeutics Limited Combined therapies using immunomodulating drugs
WO2024238387A1 (en) * 2023-05-12 2024-11-21 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025073908A1 (en) 2023-10-05 2025-04-10 Onk Therapeutics Limited Optimised il-15 constructs
WO2025146467A1 (en) 2024-01-04 2025-07-10 Onk Therapeutics Limited Targeted il-15 construct delivery
KR20250118299A (ko) 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109668A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213432A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
AU2007311002B2 (en) 2006-10-19 2012-01-12 Csl Limited Antibody antagonists of interleukin-13 receptor alpha 1
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
WO2014138704A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
CA2937750A1 (en) * 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
CA2937711C (en) * 2014-02-14 2020-10-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
PL3237436T3 (pl) 2014-12-24 2020-03-31 Aadigen, Llc Peptydy i nanocząsteczki do wewnątrzkomórkowego dostarczania cząsteczek
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2989347A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
ES2939084T3 (es) 2015-07-29 2023-04-18 Onk Therapeutics Ltd Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
DK3581190T3 (da) 2016-12-09 2021-06-07 Onk Therapeutics Ltd Manipulerede naturlige dræberceller og anvendelser deraf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109668A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Haematologica，2016年02月，Vol.101, No.5，p.616-625

Also Published As

Publication number Publication date
WO2018104562A1 (en) 2018-06-14
AU2017371517A1 (en) 2019-07-04
EP3454871A1 (en) 2019-03-20
EP3581190A1 (en) 2019-12-18
DK3454871T3 (da) 2019-09-16
CN110248669A (zh) 2019-09-17
EP3581190B1 (en) 2021-03-10
US20180161371A1 (en) 2018-06-14
ES2875005T3 (es) 2021-11-08
RU2019121509A (ru) 2021-01-11
DK3581190T3 (da) 2021-06-07
EP3895712B1 (en) 2022-06-22
BR112019011450A2 (pt) 2019-10-15
RU2019121509A3 (enExample) 2021-03-30
JP2020503891A (ja) 2020-02-06
EP4104841A1 (en) 2022-12-21
US20210046118A1 (en) 2021-02-18
JP2023052980A (ja) 2023-04-12
ES2746856T3 (es) 2020-03-09
CN117305250A (zh) 2023-12-29
MX2019006598A (es) 2019-10-15
KR20190114966A (ko) 2019-10-10
AU2017371517B2 (en) 2023-01-05
EP3895712A1 (en) 2021-10-20
CA3045386A1 (en) 2018-06-14
CN110248669B (zh) 2023-09-08
ES2926397T3 (es) 2022-10-26
US10799536B2 (en) 2020-10-13
EP3454871B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
JP7228900B2 (ja) 操作されたナチュラルキラー細胞およびその使用
US20220154190A1 (en) Altering Gene Expression in Modified T Cells and Uses Thereof
JP7372728B2 (ja) 改変ｔ細胞に関する方法および組成物
JP7447388B2 (ja) 感染性疾患の治療のための共受容体システム
US20210214415A1 (en) Immunoresponsive cells expressing dominant negative fas and uses thereof
JP2022533621A (ja) 認識分子を含む操作された免疫細胞
EP3303586A1 (en) Composition and methods for regulating inhibitory interactions in genetically engineered cells
KR20240051112A (ko) 조작된 자연 살해(nk) 세포 및 관련 방법
KR20240035798A (ko) 방법 및 조성물
US20250375524A1 (en) Combination of engineered natural killer (nk) cells and antibody therapy and related methods
RU2777284C2 (ru) Сконструированные клетки - естественные киллеры и их применение
HK40081199A (en) Engineered natural killer cells and uses thereof
HK40061900B (en) Engineered natural killer cells and uses thereof
HK40061900A (en) Engineered natural killer cells and uses thereof
HK40018917B (en) Engineered natural killer cells and uses thereof
HK40018917A (en) Engineered natural killer cells and uses thereof
HK1262291B (en) Engineered natural killer cells and uses thereof
HK1262291A1 (en) Engineered natural killer cells and uses thereof
CN117915929A (zh) 工程化自然杀伤（nk）细胞和相关方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230207

R150 Certificate of patent or registration of utility model

Ref document number: 7228900

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150